Pfizer Corporation

Mark Allen Sanner

Anton F Fliri

Kishor A Desai

Patricia A Seymour

Chris John Helal

Stevin H Zorn

Brian Thomas O'Neill

Martin James Wythes

Frank S Menniti

Mark Ian Kemp

Michael John Palmer

William Stephen Faraci

Michael K Ahlijanian

Christoper B Cooper

Lit-Fui Lau

John Adams Lowe, Iii

Christopher Blair Cooper

Anabella Villalobos

Anton F J Fliri

Antor F Fliri

Annabella Villalobos

Substituted pyrido[1,2-a]pyrazines of general formula I; wherein Ar and Arrepresent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO, CHOH, C&#x2550;O, or &#x2014;(CRR); and n is 0&#x2013;2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems: 

2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors

The present invention relates to compounds of formula I wherein Ar, Y and G are as defined in the specification, a is 1 to 4, Z and W are carbon or nitrogen and n is 1, 2 or 3; and to pharmaceutical compositions comprising the compound of formula I and a pharmaceutically effective carrier; and to a method useful in treating or preventing in mammals, including humans, a disorder or condition selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias.

Piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams

The invention provides compounds of formula 1 wherein R, R, R, and Rare as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission. Also described are pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.

Imidazole derivatives

Thiazole derivatives

Heterocyclic compounds as inhibitors of rotamase enzymes

The present invention provides a method of treating or preventing a novelty-seeking disorder, such as pathological gambling, attention deficit disorder with hyperactivity disorder and sex addiction, comprising administering a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.

Dopamine D4 ligands for the treatment of novelty-seeking disorders

This invention relates to the use of compounds of formula I

Pyrrolo&lsqb;1,2-a&rsqb;pyrazine derivatives as 5HT1A ligands

Substituted pyrido&lsqb;1,2-a&rsqb;pyrazines of general formula I; wherein Ar and Ar,represent various carbocyclic and heterocyclic aromatic rings; A represents O, S, SO, SO,, CHOH, C&boxH;O, or &mdash;(CR,R,); and n is 0-2, as well as precursors thereto, are ligands for dopamine receptor subtypes and serotonin (5HT) within the body and are therefore useful in the treatment of disorders of the dopamine and serotonin systems:

2,7-substituted octahydro-1H-pyrido&lsqb;1,2-A&rsqb;pyrazine derivatives as ligands for serotonin receptors

Benzimidazole derivatives having dopaminergic activity

Benzimidazolone derivatives with central dopaminergic activity

2,7-substituted octahydro-1H-pyrido�1,2-a!pyrazine derivatives

This invention relates to compounds of formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, X, m and n are defined as in the specification, their pharmaceutically acceptable salts and pharmaceutical compositions containing such compounds or their salts.

2,7-substituted octahydro-pyrrolo�1,2-a!pyrazine derivatives

Growing community of inventors

Old Saybrook, CT, United States of America

Mark Allen Sanner